Identification and drug-induced reversion of molecular signatures of Alzheimer’s disease onset and progression in AppNL-G-F, AppNL-F, and 3xTg-AD mouse models

[1]  K. Brennand,et al.  Molecular subtyping of Alzheimer’s disease using RNA sequencing data reveals novel mechanisms and targets , 2021, Science Advances.

[2]  G. Cantarella,et al.  Repositioning of Immunomodulators: A Ray of Hope for Alzheimer’s Disease? , 2020, Frontiers in Neuroscience.

[3]  E. McDonagh,et al.  Open Targets Platform: supporting systematic drug–target identification and prioritisation , 2020, Nucleic Acids Res..

[4]  Patrick Aloy,et al.  Bioactivity descriptors for uncharacterized compounds , 2020, bioRxiv.

[5]  Haokui Zhou,et al.  Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease , 2020, BioMed research international.

[6]  L. Schneider,et al.  The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease , 2020, Alzheimer's Research & Therapy.

[7]  D. Collier,et al.  Transcriptional Signatures of Tau and Amyloid Neuropathology , 2020, Cell reports.

[8]  K. Blennow,et al.  Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia , 2020, Nature Communications.

[9]  G. Deuschl,et al.  β-adrenoreceptors and the risk of Parkinson's disease , 2020, The Lancet Neurology.

[10]  Bin Zhang,et al.  Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer’s Disease Progression , 2020, Neuron.

[11]  Gary D. Bader,et al.  Single-cell transcriptomic profiling of the aging mouse brain , 2019, Nature Neuroscience.

[12]  P. Aloy,et al.  Extending the small molecule similarity principle to all levels of biology , 2019, bioRxiv.

[13]  R. Lipton,et al.  Naproxen for presymptomatic Alzheimer disease , 2019, Neurology.

[14]  G. Koren,et al.  Chronic Use of β-Blockers and the Risk of Parkinson’s Disease , 2019, Clinical Drug Investigation.

[15]  T. Südhof,et al.  Synaptotagmin-11 mediates a vesicle trafficking pathway that is essential for development and synaptic plasticity , 2019, Genes & development.

[16]  Evan Z. Macosko,et al.  Single‐Cell RNA Sequencing of Microglia throughout the Mouse Lifespan and in the Injured Brain Reveals Complex Cell‐State Changes , 2019, Immunity.

[17]  Ilke Sen,et al.  Transcriptomics-Based Screening Identifies Pharmacological Inhibition of Hsp90 as a Means to Defer Aging , 2018, bioRxiv.

[18]  Martin Eisenacher,et al.  The PRIDE database and related tools and resources in 2019: improving support for quantification data , 2018, Nucleic Acids Res..

[19]  T. P. Centeno,et al.  Precisely measured protein lifetimes in the mouse brain reveal differences across tissues and subcellular fractions , 2018, Nature Communications.

[20]  M. Colonna,et al.  The identity and function of microglia in neurodegeneration , 2018, Nature Immunology.

[21]  Charles C. White,et al.  A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer’s disease , 2018, Nature Neuroscience.

[22]  A. Serrano‐Pozo,et al.  Deciphering the Astrocyte Reaction in Alzheimer’s Disease , 2018, Front. Aging Neurosci..

[23]  B. Winblad,et al.  The Bri2 and Bri3 BRICHOS Domains Interact Differently with Aβ42 and Alzheimer Amyloid Plaques , 2018, Journal of Alzheimer's disease reports.

[24]  E. Diamandis,et al.  Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer’s disease , 2018, Alzheimer's Research & Therapy.

[25]  Dohyun Han,et al.  Molecular and functional signatures in a novel Alzheimer’s disease mouse model assessed by quantitative proteomics , 2018, Molecular Neurodegeneration.

[26]  Z. Yue,et al.  Synaptotagmin-11 is a critical mediator of parkin-linked neurotoxicity and Parkinson’s disease-like pathology , 2018, Nature Communications.

[27]  T. Iwaki,et al.  Comparative profiling of cortical gene expression in Alzheimer’s disease patients and mouse models demonstrates a link between amyloidosis and neuroinflammation , 2017, Scientific Reports.

[28]  T. Asada,et al.  iPSC-Based Compound Screening and In Vitro Trials Identify a Synergistic Anti-amyloid β Combination for Alzheimer's Disease. , 2017, Cell reports.

[29]  A. Regev,et al.  Temporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell Resolution , 2017, Cell reports.

[30]  B. Winblad,et al.  APP mouse models for Alzheimer's disease preclinical studies , 2017, The EMBO journal.

[31]  B. Barres,et al.  Reactive Astrocytes: Production, Function, and Therapeutic Potential. , 2017, Immunity.

[32]  Daniel B. McClatchy,et al.  Amyloid accumulation drives proteome-wide alterations in mouse models of Alzheimer’s disease like pathology , 2017, bioRxiv.

[33]  I. Amit,et al.  A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease , 2017, Cell.

[34]  Angela N. Brooks,et al.  A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles , 2017, Cell.

[35]  Lei Zhang,et al.  Analyzing the genes related to Alzheimer’s disease via a network and pathway-based approach , 2017, Alzheimer's Research & Therapy.

[36]  B. Ueberheide,et al.  Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer’s disease , 2017, Acta Neuropathologica.

[37]  Joseph Gomes,et al.  MoleculeNet: a benchmark for molecular machine learning† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c7sc02664a , 2017, Chemical science.

[38]  M. Perretti,et al.  Old drugs with new skills: fenoprofen as an allosteric enhancer at melanocortin receptor 3 , 2016, Cellular and Molecular Life Sciences.

[39]  P. Libby,et al.  Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. , 2016, The New England journal of medicine.

[40]  D. Brough,et al.  Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models , 2016, Nature Communications.

[41]  H. Heller,et al.  Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer's disease model mice. , 2016, Brain : a journal of neurology.

[42]  J. Hardy,et al.  The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.

[43]  P. Dutar,et al.  The Chemokine MIP-1α/CCL3 impairs mouse hippocampal synaptic transmission, plasticity and memory , 2015, Scientific Reports.

[44]  J. C. Wolters,et al.  Protein biogenesis machinery is a driver of replicative aging in yeast , 2015, eLife.

[45]  M. Eijken,et al.  Connectivity Map-based discovery of parbendazole reveals targetable human osteogenic pathway , 2015, Proceedings of the National Academy of Sciences.

[46]  Peer Bork,et al.  Integrated Transcriptome and Proteome Analyses Reveal Organ-Specific Proteome Deterioration in Old Rats , 2015, Cell systems.

[47]  Bruno Vellas,et al.  Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions , 2015, The Lancet Neurology.

[48]  Ralph Mazitschek,et al.  Treatment of Obesity with Celastrol , 2015, Cell.

[49]  O. Garaschuk,et al.  Neuroinflammation in Alzheimer's disease , 2015, The Lancet Neurology.

[50]  P. Khaitovich,et al.  Transcript and protein expression decoupling reveals RNA binding proteins and miRNAs as potential modulators of human aging , 2015, Genome Biology.

[51]  M. Heneka,et al.  Innate immunity in Alzheimer's disease , 2015, Nature Immunology.

[52]  F. Edwards,et al.  A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology. , 2015, Cell reports.

[53]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[54]  Wenjia Lai,et al.  Quantitative proteomics reveals that PEA15 regulates astroglial Aβ phagocytosis in an Alzheimer's disease mouse model. , 2014, Journal of proteomics.

[55]  J. Hardy,et al.  A Critique of the Drug Discovery and Phase 3 Clinical Programs Targeting the Amyloid Hypothesis for Alzheimer Disease , 2014, Annals of neurology.

[56]  P. Scheltens,et al.  BRI2-BRICHOS is increased in human amyloid plaques in early stages of Alzheimer's disease , 2014, Neurobiology of Aging.

[57]  D. Bates,et al.  Fitting Linear Mixed-Effects Models Using lme4 , 2014, 1406.5823.

[58]  F. Calon,et al.  Altered cerebral vascular volumes and solute transport at the blood–brain barriers of two transgenic mouse models of Alzheimer's disease , 2014, Neuropharmacology.

[59]  S. Itohara,et al.  Single App knock-in mouse models of Alzheimer's disease , 2014, Nature Neuroscience.

[60]  David Rossell,et al.  QUANTIFYING ALTERNATIVE SPLICING FROM PAIRED-END RNA-SEQUENCING DATA. , 2014, The annals of applied statistics.

[61]  D. Praticò,et al.  The 12‐15‐lipoxygenase is a modulator of Alzheimer's‐related tau pathology in vivo , 2013, Aging cell.

[62]  Michel Boulouard,et al.  Object recognition test in mice , 2013, Nature Protocols.

[63]  Manuel Serrano,et al.  The Hallmarks of Aging , 2013, Cell.

[64]  F. Iorio,et al.  Transcriptional data: a new gateway to drug repositioning? , 2013, Drug discovery today.

[65]  Ian F. Harrison,et al.  Prazosin, an α1-adrenoceptor antagonist, prevents memory deterioration in the APP23 transgenic mouse model of Alzheimer's disease , 2013, Neurobiology of Aging.

[66]  A. Hofman,et al.  Variant of TREM2 associated with the risk of Alzheimer's disease. , 2013, The New England journal of medicine.

[67]  M. Diamond,et al.  The broad-spectrum antiviral functions of IFIT and IFITM proteins , 2012, Nature Reviews Immunology.

[68]  Sean R. Davis,et al.  NCBI GEO: archive for functional genomics data sets—update , 2012, Nucleic Acids Res..

[69]  Frank M LaFerla,et al.  Animal models of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[70]  R. Tanzi.  The genetics of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[71]  S. Pinton,et al.  Effects of diphenyl diselenide on depressive-like behavior in ovariectomized mice submitted to subchronic stress: involvement of the serotonergic system , 2012, Psychopharmacology.

[72]  D. Selkoe,et al.  Resolving controversies on the path to Alzheimer's therapeutics , 2011, Nature Medicine.

[73]  P. Aloy,et al.  Interactome mapping suggests new mechanistic details underlying Alzheimer's disease. , 2011, Genome research.

[74]  Mohamad Saad,et al.  Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies , 2011, The Lancet.

[75]  Frank Z. Stanczyk,et al.  Sex differences in β-amyloid accumulation in 3xTg-AD mice: Role of neonatal sex steroid hormone exposure , 2010, Brain Research.

[76]  K. Lauber,et al.  Sodium Overload and Water Influx Activate the NALP3 Inflammasome , 2010, The Journal of Biological Chemistry.

[77]  K. Pandey,et al.  Targeted disruption of guanylyl cyclase-A/natriuretic peptide receptor-A gene provokes renal fibrosis and remodeling in null mutant mice: role of proinflammatory cytokines. , 2010, Endocrinology.

[78]  B. Winblad,et al.  Alzheimer's disease: clinical trials and drug development , 2010, The Lancet Neurology.

[79]  K. Zahs,et al.  Probing the Biology of Alzheimer's Disease in Mice , 2010, Neuron.

[80]  M. Citron.  Alzheimer's disease: strategies for disease modification , 2010, Nature Reviews Drug Discovery.

[81]  Takao Shimizu,et al.  The cyclooxygenase-2 selective inhibitor, etodolac, but not aspirin reduces neovascularization in a murine ischemic hind limb model. , 2010, European journal of pharmacology.

[82]  Luis Serrano,et al.  Correlation of mRNA and protein in complex biological samples , 2009, FEBS letters.

[83]  E. Marcotte,et al.  Global signatures of protein and mRNA expression levelsw , 2009 .

[84]  Yuan-yuan Wang,et al.  Therapeutic effect of {beta}-adrenoceptor blockers using a mouse model of dilated cardiomyopathy with a troponin mutation. , 2009, Cardiovascular research.

[85]  Stuart Maudsley,et al.  iTRAQ Analysis of Complex Proteome Alterations in 3xTgAD Alzheimer's Mice: Understanding the Interface between Physiology and Disease , 2008, PloS one.

[86]  T. Hothorn,et al.  Simultaneous Inference in General Parametric Models , 2008, Biometrical journal. Biometrische Zeitschrift.

[87]  Donald R. Miller,et al.  Protective effects of NSAIDs on the development of Alzheimer disease , 2008, Neurology.

[88]  M. Puig,et al.  Dexketoprofen-induced antinociception in animal models of acute pain: Synergy with morphine and paracetamol , 2007, Neuropharmacology.

[89]  M. Goedert,et al.  A Century of Alzheimer's Disease , 2006, Science.

[90]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[91]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[92]  B. Winblad,et al.  The age-dependent relation of blood pressure to cognitive function and dementia , 2005, The Lancet Neurology.

[93]  K. Parker,et al.  Multiplexed Protein Quantitation in Saccharomyces cerevisiae Using Amine-reactive Isobaric Tagging Reagents*S , 2004, Molecular & Cellular Proteomics.

[94]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[95]  Daniel R. Scoles,et al.  The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI. , 2003, Human molecular genetics.

[96]  M. Gerstein,et al.  Comparing protein abundance and mRNA expression levels on a genomic scale , 2003, Genome Biology.

[97]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[98]  A. Hofman,et al.  Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. , 2001, The New England journal of medicine.

[99]  Rong Wang,et al.  A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity , 2001, Nature.

[100]  Yuhui Liu,et al.  Sequential Treatment of SH‐SY5Y Cells with Retinoic Acid and Brain‐Derived Neurotrophic Factor Gives Rise to Fully Differentiated, Neurotrophic Factor‐Dependent, Human Neuron‐Like Cells , 2000, Journal of neurochemistry.

[101]  S. Squazzo,et al.  Aggregation of Secreted Amyloid -Protein into Sodium Dodecyl Sulfate-stable Oligomers in Cell Culture (*) , 1995, The Journal of Biological Chemistry.

[102]  D. Selkoe,et al.  Immunochemical identification of the serine protease inhibitor α 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease , 1988, Cell.

[103]  G. Landreth,et al.  UvA-DARE ( Digital Academic Repository ) Targeting Neuroinflammation to Treat Alzheimer ' s Disease , 2017 .

[104]  B. de Strooper.  Lessons from a failed γ-secretase Alzheimer trial. , 2014, Cell.

[105]  T. Bayer,et al.  Prolonged running, not fluoxetine treatment, increases neurogenesis, but does not alter neuropathology, in the 3xTg mouse model of Alzheimer's disease. , 2013, Current topics in behavioral neurosciences.

[106]  I. Ferrer,et al.  Edinburgh Research Explorer Differential overexpression of SERPINA3 in human prion diseases , 2022 .